Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Return on Health cover art

Return on Health

Return on Health

Written by: Niko Hems and Miguel Medina
Listen for free

About this listen
Health is full of strong claims, conflicting voices, and bold promises. Most people end up overwhelmed and unsure who to trust. Return on Health aims to bring clarity by listening to every side, asking hard questions, and keeping science and common sense at the center. Hosted by Niko Hems and Miguel Medina Stanivukovic, the podcast takes a clear look at longevity, prevention, performance, and the future of health. We invite researchers, founders, clinicians, skeptics, and innovators, then pressure-test their ideas. Some viewpoints will align. Others will clash. That is the point.Niko Hems and Miguel Medina Hygiene & Healthy Living
Episodes
  • Consulting Executive: Why SUCCESS Is Destroying Your HEALTH!
    Nov 8 2026

    Medical Doctor & Consulting Partner: Why SUCCESS Is Destroying Your HEALTH!

    Making partner at a major consulting firm is easier than following your own health advice. At least, that's what Dr. Andre Heeg discovered.

    As a medical doctor, dentist, and senior business leader, Andre understands the science of health. Yet he spent years sacrificing sleep, pushing through stress, and putting professional deadlines ahead of his own well-being.

    In this episode, we discuss the hidden cost of high performance, his late ADHD diagnosis, and why a trip to North Korea unexpectedly taught him the value of disconnecting.

    We also get into the controversial side of longevity: why Andre almost tried BPC-157, the dangers of chasing hundreds of biomarkers, and why more health data doesn't necessarily translate into better health.

    Andre shares how he would redesign demanding workplaces, what he learned from elite sports, and why protecting your health requires a different mindset than building a successful career.

    Can you achieve extraordinary professional success without sacrificing your health?

    Join Niko Hems and Miguel Medina for an honest conversation about ambition, burnout, longevity, and what truly delivers a Return on Health.

    Show More Show Less
    1 hr and 1 min
  • Why Investors Are Betting on Aging: Can We Actually Reverse It? | Dr. Karl Pfleger
    Oct 18 2026

    What if aging could actually be reversed? And why are investors putting money into companies trying to make it happen?

    Dr. Karl Pfleger spent a decade at Google after earning his PhD in Computer Science at Stanford. Today, he's an aging biotech investor who has backed around 30 companies working on one of the biggest challenges in medicine: reversing biological aging.

    His investment philosophy is unusually specific. He's interested in therapies that repair the molecular damage associated with aging, rather than simply slowing down the aging process.

    In this episode of Return on Health, Niko Hems and Miguel Medina speak with Karl about where the aging biotech industry is heading, which scientific breakthroughs could make the biggest difference, and what it would actually take to demonstrate that a therapy reverses aspects of human aging.

    We discuss:

    → Why Karl invests in age-reversal therapies rather than interventions that merely slow aging

    → What makes an aging biotech startup worth investing in

    → Senolytics, stem cells, and epigenetic partial reprogramming

    → Why biological age clocks aren't sufficient proof that an intervention works

    → The regulatory challenges facing aging biotech companies

    → Why immune system rejuvenation and thymus regeneration deserve more attention

    → Whether people alive today could live to 150

    → Why Karl thinks rapamycin, GLP-1 drugs, and single-intervention lifespan studies receive too much attention

    → His personal longevity routine, from exercise and nutrition to supplements and sleep medication

    → Why he believes healthcare systematically underestimates the harm of doing nothing

    Karl also explains why he thinks aging research remains severely underfunded compared with cancer research, and what needs to change to bring more therapies into clinical practice.

    Chapters

    00:00 Why invest in reversing aging?
    03:44 From Stanford and Google to aging biotech
    08:20 What would a world without biological aging look like?
    12:28 Can we reverse aging within our lifetimes?
    19:20 The ethics of radical life extension
    25:03 How Karl evaluates aging biotech investments
    31:10 What makes a biotech startup investable?
    33:12 The evidence investors want to see
    38:08 How do we prove an aging therapy works?
    44:03 Aging versus lifestyle-related disease
    50:01 The potential of thymus rejuvenation
    50:38 Karl's personal longevity routine
    56:42 Rapid-fire questions
    57:11 The most promising hallmark of aging
    58:29 What's overhyped in longevity?
    59:45 The experiments Karl would fund
    1:03:29 What needs to change in healthcare?

    About our guest

    Dr. Karl Pfleger is an aging biotech investor, former Google engineer, and Stanford-trained computer scientist. He founded AgingBiotech.info, a resource tracking companies and developments across the aging biotechnology industry.

    Learn more: https://agingbiotech.info

    About Return on Health

    Hosted by Niko Hems and Miguel Medina, Return on Health brings researchers, physicians, entrepreneurs, and critical thinkers together to question assumptions about health, medicine, and longevity.

    Subscribe for conversations about the science, business, and future of human health.

    #Longevity #AgingResearch #Biotech #AgeReversal #KarlPfleger

    Show More Show Less
    1 hr and 6 mins
  • Chronic Lyme, Mold & Alzheimer’s: What If Medicine Is Missing the Real Cause?
    Oct 4 2026

    Can chronic infections drive chronic disease?


    Dr. Richard Horowitz has spent more than four decades treating patients with complex chronic illness, including Lyme disease, long COVID, chronic fatigue, neurological symptoms and multi-system disease.

    His central argument is controversial: many chronic illnesses cannot be explained by a single diagnosis or a single cause.Instead, Horowitz proposes a framework of interacting factors including persistent infections, environmental toxins, microbiome dysfunction, intestinal permeability, nutrient deficiencies, sleep, mitochondrial dysfunction, dysautonomia and chronic inflammation.

    But how much of this is actually proven? And where does association end and causation begin?

    In this episode of Return on Health, we push Dr. Horowitz on exactly those questions.

    We discuss

    • Why some patients remain symptomatic after Lyme disease treatment

    • The debate around chronic Lyme disease and post-treatment Lyme disease syndrome

    • Borrelia, Bartonella and Babesia

    • Biofilms and bacterial persister cells

    • His 16-factor MSIDS framework for chronic illness

    • Mold exposure, mycotoxin testing and its clinical limitations

    • Heavy metals, microbiome dysfunction and intestinal permeability

    • Dysautonomia, POTS and mast cell activation

    • Why a positive test does not necessarily mean something is causing symptoms

    • How Horowitz decides which potential drivers to treat first

    • His dapsone combination protocol for chronic Lyme disease

    • The risks and required screening before dapsone treatment

    • Why observational results and clinical experience are not enough

    • The need for randomized controlled trials

    • Lyme disease, neuroinflammation and Alzheimer's disease

    • His published case involving P-tau217 and other Alzheimer's biomarkers

    • Why improving a biomarker is different from proving an effect on dementia

    • What conventional medicine may be missing, and where alternative approaches can go too far

    Horowitz himself acknowledges one of the central limitations: much of this work still needs stronger evidence capable of moving from association toward causation.

    One example is mold testing. A patient may test positive for mycotoxin exposure, but that alone cannot establish that mold is responsible for their symptoms.

    The same question comes up when we discuss Alzheimer's biomarkers. Horowitz presents cases in which P-tau217 and other biomarkers changed after treatment, while we challenge what can actually be concluded from a surrogate biomarker without clinical outcome data.

    About Dr. Richard Horowitz

    Dr. Richard Horowitz is an internal medicine physician focused on Lyme disease and complex chronic illness. He has treated more than 13,000 patients and developed the MSIDS framework discussed throughout this episode.

    His new book, Ending Chronic Illness: A Revolutionary New Program to Reverse Inflammation and Heal Persistent Disease, will be released on October 13, 2026.

    Richard Horowitz

    Website: https://cangetbetter.com/

    New book, Ending Chronic Illness: https://cangetbetter.com/Book

    Website: https://www.endingchronicillness.com/

    Return on Health

    Website: https://returnonhealth.de/Watch and listen to all episodes of Return on Health on YouTube, Spotify and Apple Podcasts.

    Return on Health is hosted by Niko Hems and Miguel Medina Stanivukovic.

    We speak with researchers, physicians, founders and skeptics about longevity, prevention and the future of health, with one rule: strong claims deserve strong questions.

    Important

    This episode discusses experimental and controversial diagnostic and treatment approaches. The views and clinical claims expressed by guests do not constitute medical advice or endorsement by Return on Health. Some approaches discussed are outside established clinical guidelines and require substantially stronger evidence.

    Show More Show Less
    1 hr and 19 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet